Tenth Circuit: Mylan’s EpiPen rebates not anticompetitive
Sanofi’s claims that Mylan illegally monopolised the market for EpiPens through exclusionary contracts and anticompetitive rebates with insurers and pharmacy benefit managers lack evidence of consumer harm, a federal appeals court has held.
Subscribe to Global Competition Review
Subscribe to unlock unlimited access
Get news, unique commentary, expert analysis and essential resources from the Global Competition Review experts.
Already have access? Login below
Copyright © Law Business ResearchCompany Number: 03281866 VAT: GB 160 7529 10